FreeTheAI

Retension Pharmaceuticals CEO Eric Keller Discloses 7.07% Stake After IPO

NeutralMedium impact
RTSN$11.64 0.09%

Eric Keller, Chief Executive Officer and co-founder of Retension Pharmaceuticals, Inc. (RTSN), reported beneficial ownership of a 7.07% stake in the company's common stock on Oct. 14, 2026. The disclosure follows the company's initial public offering on Oct. 13, 2026, and consolidates his founder shares, option grants, preferred stock conversions, and shares purchased in the IPO.

Keller holds the equity position for investment and compensation purposes to align his incentives with long-term corporate performance. As CEO and a board member, he plans to remain actively involved in strategy and governance. He indicated that he could acquire additional shares or sell stock in the future depending on market conditions.

For now, Keller's trading ability is restricted by a 180-day lock-up agreement signed during the IPO, which prevents sales, hedging, or registrations of his shares. Once the lock-up expires, he may adjust his holdings as he reviews business progress and market conditions. Retension Pharmaceuticals stock closed at 11.64 USD, up 0.09% for the day.

Key points

  • Retension Pharmaceuticals CEO Eric Keller reported a 7.07% beneficial ownership stake.
  • The filing consolidates founder shares, option grants, converted preferred shares, and IPO purchases.
  • Keller signed a 180-day lock-up agreement restricting share sales and hedging post-IPO.
  • Keller holds the stake for investment and compensation to align with long-term strategy.

Written by our AI from expert market sources across the web. It can contain mistakes: check the facts before acting on them. Write-ups powered by the free AI API at FreeTheAI.org

How we writeDisclaimer

Questions and answers

What stake does Eric Keller hold in Retension Pharmaceuticals?

Eric Keller holds a 7.07% beneficial ownership stake in Retension Pharmaceuticals, Inc., which combines his founder shares, option grants, converted preferred stock, and IPO purchases.

Is Eric Keller subject to a lock-up period on his stock?

Yes. Eric Keller signed a 180-day IPO lock-up agreement that limits sales, hedging, or registrations of his stock.

Why did Eric Keller report his ownership in Retension Pharmaceuticals?

He reported his stake following the company's Oct. 13, 2026 initial public offering to consolidate his equity holdings for investment and compensation purposes.